磷霉素联合美罗培南对肺炎克雷伯菌的体外药效学研究
采用体外药代动力学模型,研究磷霉素联合美罗培南对6株磷霉素MIC 8-1024 mg/L、美罗培南MIC 0.06->1024 mg/L的肺炎克雷伯菌的药效。联合美罗培南后,5/6株磷霉素抑菌所需fAUC/MIC降至<10,杀菌(2 log下降)所需<30,并抑制磷霉素耐药群体变化。
要点
- 磷霉素单药对5/6株肺炎克雷伯菌24小时抑菌fAUC/MIC>500。
- 联合美罗培南后5/6株抑菌fAUC/MIC<10,2 log杀菌<30。
- 联合美罗培南抑制磷霉素耐药群体变化,美罗培南群体无变化。
核心结论
- 加入美罗培南显著降低磷霉素达到抑菌和杀菌效应所需的fAUC/MIC暴露,并抑制磷霉素耐药的出现。
研究设计与样本
- 体外药代动力学稀释模型,采用6株肺炎克雷伯菌,磷霉素MIC 8-1024 mg/L,美罗培南MIC 0.06->1024 mg/L。
- 磷霉素暴露范围至fAUC/MIC 500,美罗培南对美罗培南MIC≥32 mg/L的菌株按2 g每8小时人用剂量相关暴露,对MIC<32 mg/L的菌株按半数抑菌fT>MIC暴露。
- 主要终点为24小时药物暴露后细菌负荷相对初始接种量的对数变化,并计算药效fAUC/MIC比值;通过群体谱评估耐药出现风险。
主要发现
- 磷霉素单药24小时抑菌fAUC/MIC在5/6株肺炎克雷伯菌中>500。
- 美罗培南对美罗培南MIC≤64 mg/L的菌株抑菌fT>MIC为16.6%-77.9%。
- 联合美罗培南后磷霉素fAUC/MIC均降低,5/6株抑菌fAUC/MIC<10,2 log下降fAUC/MIC<30。
- 加入美罗培南抑制磷霉素群体谱变化,联合暴露下美罗培南群体谱无变化。
关键数值与推荐
- 磷霉素单药24小时抑菌fAUC/MIC>500(5/6株)。
- 联合美罗培南时磷霉素抑菌fAUC/MIC<10(5/6株),2 log杀菌fAUC/MIC<30(5/6株)。
- 美罗培南抑菌fT>MIC为16.6%-77.9%(美罗培南MIC≤64 mg/L的菌株)。
局限性
- 美罗培南MIC>1024 mg/L的菌株未检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous fosfomycin is used in combination with other antimicrobials for the management of severe and/or multidrug resistant Gram-negative infection. We used an in vitro pharmacokinetic model to study the combination of fosfomycin plus meropenem. METHODS: Six Klebsiella pneumoniae fosfomycin MICs 8-1024 mg/L, meropenem MICs 0.06->1024 mg/L were employed. A dilutional pharmacokinetic model was used to generate fosfomycin exposure ranges up to a fAUC/MIC 500. Exposure-ranging experiments were repeated in the presence of meropenem at exposures associated with 2 g 8-hourly human dosing for strains with meropenem MICs ≥32 mg/L and at half the bacteriostatic fT > MIC for strains with MICs <32 mg/L. The log change in bacterial burden from the initial inoculum after 24 h drug exposure was taken as the primary endpoint and fAUC/MIC ratios for antibacterial effects were calculated. The risk of emergence of resistance was assessed by measurement of the population profiles. RESULTS: Fosfomycin fAUC/MIC for bacteriostatic effect at 24 h were >500 for 5/6 K. pneumoniae strains. Meropenem fT > MIC for static effect were 16.6%-77.9% for the strains with meropenem MIC ≤ 64 mg/L. Strains with MICs of >1024 mg/L were not tested. Fosfomycin fAUC/MICs in the presence of meropenem were all reduced and for 5/6 strains the fAUC/MIC for static effect was <10 and <30 for a 2 log drop. Addition of meropenem suppressed changes in fosfomycin population profiles. There were no changes in meropenem population profiles exposed to the combination. CONCLUSION: Addition of meropenem to fosfomycin had a dramatic impact on the fosfomycin fAUC/MIC exposures required for bacteriostatic and bactericidal effects and suppressed emergence of fosfomycin resistance.
引用
- MacGowan AP, Griffin P, Attwood MLG, et al. The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection. J Antimicrob Chemother. 2025. PMID: 39887074. doi:10.1093/jac/dkaf020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。